So-Young International (SY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
22 May, 2026Executive summary
Q1 2026 revenue reached RMB 432.8 million, up 45.6% year-over-year, driven by strong growth in the branded aesthetic center business.
Aesthetic center revenue rose 185.8% year-over-year to RMB 282.4 million, exceeding guidance for the fourth consecutive quarter.
The company expanded to 59 centers in 17 cities, with verified treatment visits and active users more than doubling year-over-year.
Operational efficiency improved, with 41 profitable centers and 48 generating positive operating cash flow.
Net loss attributable was RMB 49.2 million, compared to RMB 33.1 million in Q1 2025; non-GAAP net loss was RMB 46.6 million.
Financial highlights
Gross margin for the aesthetic center business reached 27%, up 8.4 percentage points year-over-year.
Gross profit was RMB 181.8 million, with a gross margin of 42.0% on total revenue.
Cash and equivalents stood at RMB 880 million as of March 31, 2026, down from RMB 936.4 million at year-end 2025 due to strategic expansion investments.
Cost of revenue increased 65.8% year-over-year to RMB 251 million, mainly from center expansion.
Operating expenses rose 26.6% year-over-year to RMB 239.7 million, with sales and marketing up 33.7%.
Outlook and guidance
Q2 2026 aesthetic treatment service revenue expected between RMB 307 million and RMB 317 million, representing 102.6% to 119.5% year-over-year growth.
Continued focus on supply chain optimization, medical delivery excellence, and operational efficiency to drive sustainable growth and profitability.
Guidance reflects current market and operating conditions, subject to change.
Latest events from So-Young International
- Q4 revenue surged 25% YoY as branded centers drove growth and net loss narrowed sharply.SY
Q4 202525 Mar 2026 - Goodwill impairment drove a net loss, but aesthetic center revenue grew over 700% year-over-year.SY
Q4 202417 Mar 2026 - Branded centers drove a 551% surge in treatment services revenue amid overall revenue decline.SY
Q1 202517 Mar 2026 - Aesthetic treatment services revenue soared 426% YoY, now the largest segment, with 50 centers targeted by year-end.SY
Q2 202517 Mar 2026 - Q2 revenue exceeded guidance, profit improved, but Q3 revenue is expected to decline.SY
Q2 202423 Jan 2026 - Q3 revenue exceeded guidance, with strong clinic and medical product growth and higher profitability.SY
Q3 202413 Jan 2026 - Aesthetic treatment revenues jumped 305% YoY, but higher costs led to a net loss.SY
Q3 202517 Nov 2025